Shots: Shots:

• The companies enter into a collaboration to test RNA-based NTRK gene fusions in colorectal and thyroid cancer patients- enrolled in the Sponsored Testing Program
• The sponsored Test4TRK program will provide RNA-based NTRK gene fusions test along with Pan-TrK IHC test in mCRC patients (high MSI-H status/deficient DNA MMR) as wells as in patients with RAIR DTC
• The study shows >3% NKTR gene fusion prevalence in mCRC patients and 2.4-12% prevalence in RAIR DTC patients with less favorable disease outcomes- irrespective of the results Bayer will be responsible for the total cost of NKTR gene fusions test

Click here ­to­ read full press release/ article | Ref: NeoGenomics | Image: Yahoo Finance